ASCO 2015: Latest developments in multiple myeloma

ASCO 2015: Latest in chronic lymphocytic leukaemia

Comment: Eribulin extends overall survival for advanced liposarcoma and leiomyosarcoma

Dasatinib plus intensive chemo versus stem cell transplant for Philadelphia chromosome positive ALL

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis

Targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Extensive lymph node surgery may not be necessary for some patients with melanoma

Effective adjuvant chemotherapy for high-risk, localised prostate cancer

Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Extensive lymph node surgery may not be necessary for some patients with melanoma